Fact-checked by Grok 2 weeks ago

Miles Laboratories

Miles Laboratories was an American pharmaceutical company founded in 1884 as the Dr. Miles Medical Company in Elkhart, Indiana, by physician Franklin Lawrence Miles to market proprietary remedies for nervous disorders and other ailments, including the flagship product Dr. Miles' Nervine. The firm expanded into over-the-counter consumer health products, most notably introducing Alka-Seltzer in 1931, which became one of its best-selling items due to its effervescent antacid formula and iconic advertising campaign featuring the slogan "Plop, plop, fizz, fizz. Oh, what a relief it is." Other key products included One-A-Day vitamins and Bactine antiseptic. Privately held for nearly a century, Miles Laboratories was acquired by Bayer AG in 1978 for $253 million, marking Bayer's major entry into the U.S. consumer health market, after which it operated as a subsidiary until the Miles brand was phased out in the mid-1990s.

Founding and Early Development

Establishment by Dr. Franklin Miles

Dr. Franklin L. Miles (1845–1929), a specializing in eye and ear diseases, practiced medicine in , during the late 19th century, where he developed proprietary remedies based on his clinical observations. In 1882, Miles formulated his first notable product, Dr. Miles' Restorative Nervine, a tonic aimed at treating nervous disorders, which he initially dispensed to patients through his practice. This marked the beginning of his shift from general medical services to commercial production of patent medicines, leveraging mail-order diagnostics and sales to reach a broader audience beyond local consultations. By the early , Miles expanded his formulations to include additional remedies such as Restorative Nerve and Liver Pills and a general , bottling them for systematic distribution rather than ad hoc preparation. Recognizing the potential for scaled of these non-prescription treatments, he established the Dr. Miles Medical Company as a dedicated entity for production and sales, formalizing operations in —a location chosen for its accessibility and Miles' established presence there. The company's model emphasized sales via advertisements in periodicals, bypassing traditional pharmacies and emphasizing Miles' personal endorsement as a credentialed . The firm was officially incorporated on , 1885, with an initial capitalization of $25,000, positioning Miles as and enabling structured of his core products. This laid the groundwork for Miles Laboratories' growth, rooted in the era's industry, where efficacy claims often relied on anecdotal testimonials rather than rigorous clinical trials, though Miles' medical background provided a veneer of legitimacy. Early operations focused on as the flagship offering, promoted for relieving headaches, , and , with production housed in modest facilities that would expand as demand grew through national advertising campaigns.

Initial Operations and Patent Medicines

Dr. Franklin Miles established the Dr. Miles Medical Company in Elkhart, Indiana, in 1884, initially focusing on the production and sale of patent medicines derived from his medical practice. The company's early operations centered on bottling proprietary remedies, with Dr. Miles Restorative Nervine serving as the flagship product—a bromide-based sedative syrup marketed as a calmative for conditions including nervousness, headaches, neuralgia, hysteria, and sleeplessness. This tonic, introduced around the company's founding, relied on trade secrecy rather than patents for its formula, typical of patent medicines which promised relief without disclosing ingredients or requiring prescriptions. Initial manufacturing occurred at a modest facility in Elkhart, where the company quickly achieved profitability within five years by distributing products through direct and mail-order channels. Marketing efforts included the distribution of almanacs, calendars, and advisory publications like "Medical News," which promoted alongside general health advice to build consumer trust and drive sales. By the late , annual advertising expenditures reached approximately $200,000, supporting the printing of millions of promotional materials such as 6.5 million almanacs and "Little Books" series. dominated early revenue, comprising a major portion of sales until the mid-1930s, reflecting the era's reliance on such remedies before stricter regulatory oversight. The company's approach emphasized empirical over scientific validation, with positioned as a versatile for nervous disorders—a later recognized as a precursor to modern tranquilizers. Operations expanded with the 1890 opening of a "Grand " in Elkhart, facilitating broader distribution while maintaining control over resale pricing through consignment contracts and proprietary association agreements. These practices underscored the initial business model's focus on proprietary control and aggressive in a competitive market of unregulated nostrums.

Product Innovation and Expansion

Development of Alka-Seltzer and Effervescent Formulas

The development of Alka-Seltzer at Miles Laboratories addressed the demand for rapid-relief medications amid the 1928 influenza epidemic, which affected millions and underscored the limitations of existing remedies for symptoms like headaches and indigestion. Company executive A.H. "Hub" Beardsley, son of president Walter Beardsley, spearheaded the initiative by directing chemists to innovate effervescent formulations, building on prior Miles products such as Nervine, a sedative available in effervescent tablet form since the early 20th century. Beardsley's vision emphasized combining active ingredients with effervescent agents—typically sodium bicarbonate and citric acid—to create fizzing tablets that dissolved quickly in water, enhancing bioavailability compared to solid pills. Head chemist J. Maurice Treneer, who joined Miles around 1911, perfected the stable technology critical to , overcoming challenges in formulation stability and ingredient compatibility after years of experimentation. The final product integrated aspirin for pain relief with components, producing upon dissolution for the characteristic that facilitated faster absorption. Initial testing occurred on December 20, 1930, with market introduction following in February 1931 and U.S. registration for "Alka-Seltzer" on June 9, 1931, as an "anti-acid effervescent preparation." This effervescent innovation marked a pivotal advancement for Miles, shifting from traditional medicines to modern over-the-counter formats and driving sales growth from $1.7 million in 1930 to higher figures post-launch, as the product's dual analgesic-antacid action appealed to consumers seeking and upset stomach remedies. Treneer's method for producing consistent, shelf-stable effervescent tablets influenced subsequent Miles formulations, though remained the cornerstone, with its basic composition enduring into later decades.

Vitamins and Other Consumer Health Products

Miles Laboratories entered the vitamin market in the early 1940s amid rising consumer demand for nutritional supplements following advancements in research and synthesis. The company's inaugural product, One-A-Day, was introduced in October 1940 as the first available in a single daily tablet formulation, combining vitamins A, B1, B2, C, and D to simplify supplementation compared to multi-dose regimens prevalent at the time. This innovation positioned One-A-Day as a convenient option for adults, with Miles emphasizing its completeness for daily nutritional needs in marketing campaigns. Building on this success, Miles expanded its vitamin line to target children, launching Chocks in 1960 as the first chewable multivitamin designed specifically for pediatric use, featuring candy-like flavors to encourage compliance. In 1968, the company introduced , licensing the popular cartoon characters to create appealing, character-shaped tablets that further boosted sales among families by associating supplementation with entertainment. These products contributed to Miles' dominance in the growing over-the-counter segment, with formulations tailored to age-specific needs, including iron-fortified variants. Beyond vitamins, Miles developed Bactine around 1950 as a key consumer health for first-aid treatment of minor wounds, scrapes, and burns. Bactine combined the benzalkonium chloride for germ-killing with lidocaine for localized pain relief, offering a dual-action formula that differentiated it from basic antiseptics and addressed consumer preferences for multifunctional products. This expansion reflected Miles' strategy of leveraging proprietary formulations in non-prescription health aids, alongside its vitamin portfolio, to capture broader market share in household remedies.

Marketing and Business Practices

Advertising and Distribution Strategies

Dr. Miles Medical Company, founded in , relied heavily on print to promote its proprietary medicines, such as Restorative Nervine, targeting ailments like nervousness and headaches. By , the company had invested $2,000,000 in efforts, including advertorials in medical publications and widespread distribution of promotional materials. These materials encompassed 6.5 million almanacs, calendars, and "Little Books" designed to build recognition among consumers, particularly women, as evidenced by targeted campaigns in 1906. Annual expenditures reached approximately $200,000 in the early , utilizing newspapers, flyers, and local press printing to maximize reach while controlling costs. For distribution, the company established a network involving over 400 wholesalers (jobbers) and 25,000 retailers (druggists), facilitating nationwide access to its products through a direct contract plan. In 1890, it opened the "Grand Dispensary" in , offering medical advice alongside product sales to build consumer and engagement. This hybrid approach combined proprietary retail outlets with broader wholesale channels, later extending to consignment arrangements to maintain over product flow. With the launch of in 1931, Miles shifted toward broadcast media, initiating radio spots in January 1932 on WLS Chicago and sponsoring programs like the "Saturday Night Barn Dance" in 1933, which expanded nationally via the . Early slogans such as "Be wise-alkalize" emphasized the product's effervescent benefits, while pre-World War II budgets for alone approached $4-5 million annually. The introduction of the Speedy mascot in 1951, debuting on in 1954, marked a pivot to visual campaigns, with the character appearing in over 100 spots; peaked at 72% of the $23.5 million total budget in 1960. The 1940 rollout of One-A-Day vitamins further diversified promotional efforts, with Wade Advertising handling campaigns featuring the tagline "Look for the big one on the package" and driving product into distributors' warehouses for rapid . Iconic jingles like "Plop, Plop, Fizz, Fizz, Oh What a Relief It Is," developed later but rooted in effervescent product branding, underscored Miles' focus on memorable, product-centric messaging across media. Distribution evolved to support these consumer-facing innovations, emphasizing national wholesale and retail networks to align with intensified .

Resale Price Policies

Dr. Miles Medical Company established policies through bilateral contracts with wholesalers and retailers to enforce minimum prices on its proprietary medicines, such as Restorative Nervine and anti-pain extracts. These agreements required wholesalers to sell only to approved retailers at fixed wholesale prices and prohibited retailers from offering discounts or selling below stipulated retail levels, aiming to prevent price-cutting that could erode brand goodwill by associating low prices with inferior quality. Wholesale consignment contracts, executed with over 400 jobbers, treated goods as consigned with title retained by the company until resale; minimum prices included $8 per dozen for $1 retail items, $4 per dozen for 50¢ items, and $2 per dozen for 25¢ items, with sales restricted to designated retail agents. Retail agency contracts, signed by approximately 25,000 dealers, mandated purchases at these wholesale rates and resale at full printed prices without quantity discounts or sales to unauthorized parties. Limited allowances included a 1 percent cash discount for payments within ten days and trade discounts of 3 percent for orders over $15 or 5 percent over $50 at wholesale, but no such reductions at retail. Enforcement relied on contract provisions for immediate termination upon violation, clawback of unearned commissions, $25 penalties per retail infraction, serial number tracking for monitoring, and demands for return of unsold goods. After the 1911 Supreme Court decision in Dr. Miles Medical Co. v. John D. Park & Sons Co. deemed these contracts per se illegal under the for restraining trade, Miles Laboratories shifted to state fair trade laws. Enacted starting in in 1931 and spreading to over half the states, these laws authorized minimum resale prices for trademarked goods via agreements binding even non-signers, exempted federally by the Miller-Tydings Act of 1937 and McGuire Act of 1952. Miles actively litigated under fair trade statutes to uphold prices, as in Miles Laboratories v. Seignious (1939), where the company argued that sub-price sales assaulted , and Miles Laboratories v. Eckerd (1954), challenging non-signer clauses but affirming enforcement against knowing discounters. These practices persisted until the federal exemptions' repeal via the Consumer Goods Pricing Act of 1975, after which Miles discontinued contracts amid declining state adoptions. The policies reflected a strategy to stabilize margins and promote uniform marketing of effervescent and patent remedies amid competitive drug markets.

Antitrust Litigation Including Dr. Miles v. Park (1911)

In the early 1900s, Dr. Miles Medical Company implemented a system of to control the pricing of its proprietary medicines, which were sold without patents but protected by trade secrets and . The company required wholesalers and jobbers to sign contracts agreeing to resell the products only at fixed list prices to retailers, who in turn were bound to maintain those prices in sales to consumers; violations led to termination of supply. This network aimed to prevent price-cutting that Miles argued would undermine the perceived value and quality of its remedies, such as Restorative Nervine, by ensuring uniform pricing nationwide. John D. Park & Sons Company, a Cincinnati-based wholesale drug distributor and former customer of Miles, began procuring the medicines through indirect channels, including from jobbers who breached their contracts, and resold them at discounts below the stipulated prices. Park's actions, which included inducing retailers to purchase the cut-rate goods, prompted Miles to file suit in in the for the Southern District of , seeking an to enforce the contracts and halt the interference. The lower court dismissed the bill, ruling the price-fixing agreements invalid as restraints of trade under the of 1890, a decision affirmed by the Sixth of Appeals in 1910. The U.S. granted and, in a decision authored by Justice Hughes on April 3, 1911, upheld the lower courts in Dr. Miles Medical Co. v. John D. Park & Sons Co., 220 U.S. 373, declaring vertical agreements on minimum resale prices per se illegal under Section 1 of the Sherman Act. The Court reasoned that such contracts, lacking patent protection, improperly restrained trade by limiting the freedom of purchasers to sell as they chose after acquisition, prioritizing against combinations that fix prices over the manufacturer's interest in goodwill preservation. This ruling invalidated Miles' entire distribution contract system, exposing the company to potential loss of control over its pricing and prompting shifts toward alternative strategies, though it did not immediately dismantle the business. The Dr. Miles precedent shaped early 20th-century antitrust enforcement against , influencing subsequent challenges to similar practices in the pharmaceutical and consumer goods sectors until its partial overruling in Leegin Creative Leather Products, Inc. v. PSKS, Inc. (2007), which subjected vertical price restraints to rule-of-reason analysis rather than illegality. For Miles Laboratories, the case highlighted vulnerabilities in enforcing uniform pricing without legal monopolies, contributing to broader scrutiny of its marketing methods amid rising competition from generic and cut-rate sellers.

Federal Trade Commission Actions and State Challenges

In 1942, the (FTC) investigated Miles Laboratories' advertising and labeling practices for products including vitamin preparations, concluding that the company's materials failed to adequately disclose potential health risks from excessive ingestion of ingredients such as nicotinic acid, which could cause flushing or gastrointestinal distress. Miles preemptively sued the in the U.S. District Court for the District of Columbia, seeking a that the agency lacked authority to regulate such disclosures under the Act, as the products were not deemed misbranded under the Food, Drug, and Cosmetic Act. The district court dismissed the suit in 1943, ruling that the possessed jurisdiction over misleading advertising claims, even absent formal misbranding. On appeal, the U.S. Court of Appeals for the D.C. Circuit affirmed in 1944, holding that the Act empowered the commission to address advertisements inducing purchase through material misrepresentations or omissions about product safety and efficacy, thereby allowing the to proceed with a potential cease-and-desist order. Miles also faced scrutiny over Alka-Seltzer advertising claims regarding "systemic acidity," where the challenged assertions that the product neutralized acid conditions throughout the body beyond mere antacid effects. In response, Miles agreed to discontinue such representations and to submit future advertising copy to the for review, avoiding formal litigation but acknowledging regulatory oversight on unsubstantiated therapeutic claims. State-level challenges primarily targeted Miles' efforts to enforce (RPM) in jurisdictions without laws legalizing minimum pricing contracts. In , a non-fair-trade state, the prosecuted Miles in 1955 for violating antitrust statutes by refusing to supply the discounter Milgram Food Stores with after it sold below stipulated prices, inducing wholesalers to withhold products, and implementing policies against dealing with price-cutters. Although no explicit price-fixing agreements were proven, the upheld a $5,000 fine against Miles, deeming the coordinated refusals to deal an unlawful combination in under state . Similarly, in , which invalidated its act on constitutional grounds in 1954, Miles encountered resistance to RPM enforcement, as courts rejected vertical absent statutory authorization, limiting the company's ability to restrict discounting by retailers like Eckerd. These actions highlighted tensions between Miles' nationwide RPM system—upheld federally under exemptions like the Miller-Tydings Act—and state antitrust in holdout jurisdictions, where such practices were viewed as anticompetitive exclusions rather than protected branding strategies.

Acquisition and Integration

Bayer's Takeover in 1978

In January 1978, AG's subsidiary, Rhinechem Corporation, completed the acquisition of Miles Laboratories Inc. for $250 million, marking a significant expansion for the German pharmaceutical giant into the American over-the-counter consumer health sector. This deal followed an informal overture in September 1977, when disclosed an offer of at least $40 per share, valuing Miles at nearly $216 million, amid negotiations that addressed Miles' board resistance and demands for a higher price. The takeover integrated Miles' portfolio of established brands, including antacid tablets and One-A-Day vitamins, which generated substantial annual revenues— alone accounted for over $100 million in sales by the mid-1970s—providing with immediate denied since its U.S. aspirin trademarks were seized as enemy property during and transferred to Inc. Strategically, the acquisition aligned with Bayer's goal of achieving over $1 billion in U.S. sales by 1980, leveraging Miles' Elkhart, Indiana-based and distribution infrastructure to bypass barriers from prior antitrust constraints and wartime losses. Miles, founded in as a privately held entity focused on patent medicines and later ethical drugs, had evolved into a mid-sized firm with diversified products but faced competitive pressures in the consumer remedies market, making it an attractive target for Bayer's diversification beyond industrial chemicals and prescription pharmaceuticals. Post-acquisition, Miles operated as a , retaining its name initially while contributing to Bayer's North American foothold, though subsequent regulatory scrutiny from the in 1979 required divestitures of overlapping units to address monopoly concerns in certain product lines. The transaction, executed without major public shareholder revolts despite Miles' private status transition, underscored Bayer's aggressive globalization amid the era's economic recovery, with Miles' 1977 revenues exceeding $300 million bolstering the combined entity's scale.

Operational Changes and Restructuring

Following Bayer's acquisition of Miles Laboratories in 1978, the company initially operated as a , serving as the for Bayer's U.S. pharmaceutical activities while retaining its base in . Miles maintained its product focus on over-the-counter remedies like and expanded into diagnostics and , with research expenditures rising from $25 million pre-acquisition to $100 million by 1985. In 1986, Bayer relocated its overall U.S. to , , but Miles' core operations remained in Elkhart. By 1991, Bayer consolidated its U.S. subsidiaries into a single entity named Miles Inc., headquartered in , to streamline management of its American operations. This integration continued in 1994 after Bayer's purchase of , when Miles Inc. was renamed , unifying branding and incorporating Sterling's over-the-counter products into Miles' consumer care division. The name change took effect on April 1, 1995, aligning U.S. operations more closely with the parent company's global identity. Restructuring accelerated in the late 1990s amid cost efficiencies and global realignments, leading to significant operational shifts in Elkhart. In 1999, Bayer closed its Consumer Care Division facility there, eliminating 550 jobs and marking the end of major production in the original Miles campus. Additional divisions were relocated or sold, including facilities transferred to Siemens Corporation, contributing to a workforce reduction from peak levels in the thousands to a fraction by the early 2000s. By 2002, Bayer placed its 1-million-square-foot Elkhart diagnostics plant on the market for $1 million, closing it later that year and shifting production to facilities in Bitterfeld, Germany, as part of broader corporate cost-cutting. In 2005, the Diabetes Care headquarters moved from Elkhart to Tarrytown, New York, cutting 100 of 160 positions. These changes reflected Bayer's strategy to centralize high-value functions and offshore manufacturing, diminishing Elkhart's role from a primary hub to minimal presence, with the last regional facility in nearby Mishawaka closing in 2020 after an 18-month wind-down affecting 200 employees.

Legacy and Economic Impact

Influence on Consumer Pharmaceuticals

Miles Laboratories exerted considerable influence on the consumer pharmaceuticals landscape by pioneering convenient, branded over-the-counter (OTC) formulations that emphasized action, daily dosing, and targeted relief for everyday ailments, shifting consumer preferences toward self-administered remedies. The company's evolution from 19th-century patent tonics to mid-20th-century innovations facilitated broader access to affordable products, supported by rigorous that educated and habituated users to branded . A cornerstone was the 1931 launch of , an blending aspirin for effects with and for properties, designed to alleviate headaches, , and cold symptoms through quick dissolution in water. This formulation addressed the limitations of dry tablets by providing audible fizzing and faster absorption, positioning it as a versatile remedy that captured significant market share, including as a leading hangover treatment, with annual U.S. sales exceeding $90 million by the 1970s. Alka-Seltzer's prominence stemmed partly from Miles' early adoption of mass , including radio spots from 1933 and television campaigns from 1949 featuring humorous jingles like "Plop, Plop, Fizz, Fizz," which normalized direct consumer engagement with OTC drugs and influenced competitive branding strategies across the category. However, scrutiny in 1938 over "systemic acidity" claims underscored regulatory pushback against expansive therapeutic assertions. In the vitamins sector, Miles introduced One-A-Day in 1940, the first formulated for single daily ingestion, combining essential nutrients to promote preventive health amid rising nutritional awareness post-Depression and wartime . This convenience-driven approach—later enhanced with minerals and iron—spurred category growth, enabling consumers to address dietary gaps without multiple doses, and paved the way for Miles' expansions into children's products like chewable Chocks and licensed vitamins in the . By simplifying supplementation, One-A-Day helped legitimize vitamins as routine consumer staples, though its success relied on that amplified perceived benefits amid limited empirical mandates for such products at the time. Miles further shaped first-aid antiseptics with Bactine's 1950 debut, a quaternary compound-based solution that dominated sales and into the late through effective germ-killing claims and family-oriented . This product's emphasis on household utility reinforced OTC antiseptics as essential for minor wounds, influencing formulations that prioritized safety and ease over prescription alternatives. Collectively, these advancements under Miles' leadership—bolstered by internal research and diversification—elevated consumer pharmaceuticals from niche remedies to ubiquitous household items, though subsequent FDA regulations on labeling and efficacy curbed some promotional freedoms established in Miles' heyday.

Long-Term Effects on Elkhart, Indiana

Miles Laboratories, founded in Elkhart, Indiana, in 1884, grew into the city's largest employer, peaking at approximately 3,300 workers by the mid-20th century, with operations spanning manufacturing of over two dozen consumer products including Alka-Seltzer. Following its acquisition by Bayer AG in 1978, the company underwent gradual operational shifts that diminished its local footprint, culminating in significant plant closures and headquarters relocation. By 1992, Bayer's exit of major facilities marked the departure of a key economic anchor, comparable in scale to the loss of a dominant industry player, which strained local fiscal and employment metrics as referenced in analyses of Elkhart County's economic vulnerabilities. Post-acquisition restructuring accelerated after 1995, when Miles Inc. rebranded as Bayer Corp., leading to a steady exodus of divisions and personnel from Elkhart; this included the closure of a 1-million-square-foot facility on Miles Avenue in late 2002, displacing about 500 remaining workers and requiring $20 million in demolition costs. Further consolidations, such as the 2005 announcement of additional plant shutdowns and the 2019 closure of Bayer's final Michiana operations after nearly 50 years, exacerbated job losses tied to the original Miles legacy. These events contributed to a persistent "hole" in Elkhart's economy, with the firm's departure cited as causing both logistical disruptions and emotional impacts on a community where it had employed a substantial portion of the workforce. Long-term repercussions included a pivot toward other sectors, notably recreational vehicle manufacturing, which absorbed some displaced labor but did not fully offset the pharma-era stability; the site's , including of remaining structures between 2011 and 2012, repurposed former Miles/ buildings for nonprofits like the Food Technology Center by 2003, signaling a shift from high-volume production to diversified, lower-density uses. This transition underscored Elkhart's vulnerability to single-employer dominance, with historical accounts noting enduring "heartaches" from the loss of a firm that had anchored growth since the late , influencing local demographics and infrastructure planning into the .

References

  1. [1]
    IHB: Dr Franklin L Miles - IN.gov
    Miles Medical Company 1885 to sell Dr. Miles' Nervine, Restorative Nerve and Liver pills, and other medicines; Miles was a Director and President of company.
  2. [2]
    Miles Labs - Indiana Historical Society
    Miles Labs, started by Dr. Franklin Miles, produced Nervine, One-a-day vitamins, Bactine, and Alka-Seltzer. It was sold to Bayer in 1978 and moved out of ...
  3. [3]
    History | Bayer Global
    Sep 9, 2025 · In the U.S., the company acquired Cutter Laboratories Inc. in 1974 and Miles Laboratories Inc. in 1978. This allowed Bayer to gain an ...
  4. [4]
    History of MILES LABORATORIES - FundingUniverse
    Share prices had risen from $24 to $41 a share once rumors of a takeover had begun circulating, and in the end Bayer paid $47 a share, or a total of $253 ...
  5. [5]
    Dr Franklin Miles (1845-1929) - Find a Grave Memorial
    He was the founder and president of the present-day Miles Laboratories in Elkhart IN, which is world famous for the manufacturing and distribution of over-the- ...Missing: date | Show results with:date
  6. [6]
    Miles Laboratories - Ad Age
    Sep 14, 2003 · Miles Laboratories dates to the early 1880s, when Franklin L. Miles, a country doctor in Elkhart, Ind., began bottling Restorative Nervine.Missing: date | Show results with:date
  7. [7]
    Talk chronicles life of Dr. Miles | Local News | goshennews.com
    Dec 5, 2017 · Seven years later, Miles developed his product, “Dr. Miles Restorative Nervine,” in 1882 which would launch the Miles Medical Co.Missing: biography | Show results with:biography
  8. [8]
    Dr. Franklin L. Miles - The Historical Marker Database
    Incorporated Grand Dispensary Medical Company 1904; sold drugs and diagnosed patients by mail. Miles moved to Florida 1906; became a farmer. Medical Company's ...Missing: biography establishment
  9. [9]
    Miles Laboratories | Encyclopedia.com
    Since 1977 Miles Laboratories has been a subsidiary of Bayer, the huge West German manufacturer, Miles Laboratories is now the focal point of Bayer's growing ...
  10. [10]
    Elkhart The business of the Dr. Miles Medical Company ... - Facebook
    Oct 12, 2022 · The business was incorporated in 1885, and is capitalized at twenty-five thousand dollars. Dr. Franklin Miles is president, George E. Compton ...“Plop, Plop, Fizz, Fizz, Oh What A Relief It Is” Miles Laboratories was ...franklin miles, md, ll. b. - FacebookMore results from www.facebook.com<|control11|><|separator|>
  11. [11]
    [PDF] The Life and Times of Dr. Miles Medical Company Rudolph JR Peritz
    A number of today's mouthwashes, cough syrups and cold medications began as patent medicines and retain their brand popularity as well as their core ingredient ...
  12. [12]
    Iconic Alka Seltzer developed at Elkhart's Miles Laboratory
    Dec 11, 2016 · The origin of Alka Seltzer traces back to the seasonal flu epidemic that spread across the United States in 1928.
  13. [13]
    Miles Nervine Effervescent Tablets
    A sedative for the following functional nervous disturbances: nervous headache, sleeplessness and restlessness, nervous irritability and excitability.Missing: formulas invention
  14. [14]
    J. MAURICE TRENEER, MADE ALKA.SELTZER
    Alka-Seltzer, a Miles spokesman said today, is still basically the same product as that developed by Mr. Treneer in 1931 and marketed the following year.<|separator|>
  15. [15]
    On June 9, 1931, Dr. Miles Medical Company's patent for "Alka ...
    Jun 9, 2019 · The Elkhart company's "anti-acid effervescent preparations" were first developed by Dr. Miles' chemist Maurice Treener after a flu epidemic ...
  16. [16]
    A Brief History of Flintstones Vitamins - Mental Floss
    Oct 21, 2010 · In 1960, the vitamin giant Miles Laboratory, owners of the One-a-Day label, developed Chocks, the first chewable vitamin aimed at children.
  17. [17]
    Best Flintstones vitamins | WGN-TV
    Aug 9, 2022 · At a time when vitamins were big and bulky and hard to swallow, Miles Laboratories introduced the first chewable vitamin for children in 1960.<|separator|>
  18. [18]
    [PDF] Olmsted 200
    Nov 1, 2021 · Other well-known products introduced by Miles Laboratories included One- a-Day Vitamins in 1940, Bactine in 1950 and. Flintstones Vitamins in ...
  19. [19]
    Balm of America: Patent Medicine Collection - History
    Bactine. Date made: c. 1948. maker: Miles Laboratories. Description: The indications or uses for this product as provided by the ...
  20. [20]
    Dr. Miles Restorative Nervine - Bay Bottles
    Sep 13, 2025 · Miles Restorative Nervine, later called simply Miles Nervine, was a patent medicine that was on the market from the mid-1880's up through the ...
  21. [21]
    DR. MILES MEDICAL COMPANY, Petitioner, v. JOHN D. PARK ...
    Miles Medical Company, an Indiana corporation, if engaged in the manufacture and sale of proprietary medicines, prepared by means of secret methods and formulas ...
  22. [22]
    Miles Laboratories v. Seignious, 30 F. Supp. 549 ... - Justia Law
    It proceeds upon the theory that the sale of identified goods at less than the price fixed by the owner of the mark or brand is an assault upon the good will, ...
  23. [23]
    [PDF] Fair-Trade under State and Federal Law
    Hence, a minimum resale price may be prescribed in all fair-trade states but not necessarily a stipulated price. The new McGuire Act will recognize either.
  24. [24]
    [PDF] "Non Signer" Clause in State Fair Trade Act Held Unconstitutional
    ' This aid was in the form of resale price maintenance,' a system which is brought about by a "vertical trade agreement" by which the manufacturer of a branded ...
  25. [25]
    Miles Laboratories v. Eckerd :: 1954 :: Florida Supreme ... - Justia Law
    With the effect of the McGuire Act disposed of the only question left goes to the constitutional validity of the non-signer clause of the Florida Fair Trade Act ...
  26. [26]
    [PDF] Resale Price Maintenance by an Integrated Firm - Chicago Unbound
    Eastman Kodak and Miles Laboratories have already chosen the latter by can- celling their fair-trade contracts. In seeking to avoid the decision a ...
  27. [27]
    Dr. Miles Medical Co. v. John D. Park & Sons Co. | 220 U.S. 373 ...
    The complainant, Dr. Miles Medical Company, an Indiana corporation, is engaged in the manufacture and sale of proprietary medicines, prepared by means of ...
  28. [28]
    SUIT CHARGES FTC OVERSTEPS POWERS; Firm, in First Case of ...
    Miles Laboratories sues for declaratory judgment on FTC powers on labeling and ad, Elkhart, Ind.
  29. [29]
    Miles Laboratories v. Federal Trade Commission, 50 F. Supp. 434 ...
    Miles Laboratories v. Federal Trade Commission, 50 F. Supp. 434 (D.D.C. 1943) case opinion from the U.S. District Court for the District of Columbia.
  30. [30]
    Miles Laboratories v. Federal Trade Commission - vLex Case Law
    Decision Date, 07 February 1944 ; Docket Number, No. 8595.,8595. ; Citation, Miles Laboratories v. Federal Trade Commission, 140 F.2d 683, 78 U.S.App.D.C. 326 ( ...
  31. [31]
    State v. Miles Laboratories :: 1955 :: Supreme Court of Missouri ...
    ... action violated the Missouri anti-trust statutes. Having found that "no price-fixing agreements were shown or proved by the evidence," our commissioner ...
  32. [32]
    COMPANY NEWS - The New York Times
    Aug 17, 1979 · The F.T.C. brought an antitrust case alleging that the acquisition substantially reduced competition in the allergenic extracts industry.
  33. [33]
    BAYER SEEKS TO BUY MILES LABORATORIES IN UNOFFICIAL ...
    Sep 27, 1977 · Bayer AG offers 'at least' $40 a share-nearly $216-million--for Miles Labs; illus (M)
  34. [34]
    Bayer discloses bid to buy Miles Laboratories - ACS Publications
    West Germany's Bayer A.G. is making a strong move to increase its U.S. holdings with its announced bid for Miles Laboratories of Elkhart, Ind. Bayer has ...
  35. [35]
    Bayer USA changing name, becoming operating company - UPI
    Sep 24, 1991 · Bayer USA said Tuesday it will transform its operating companies into a single company called Miles Inc. at the start of next year....Missing: 1995 | Show results with:1995
  36. [36]
    Bayer A.G. - Company-Histories.com
    1978: Miles Laboratories is acquired. 1982: The firm restructures, creating ... The following year Bayer purchased Miles Laboratories, manufacturers of Alka- ...Missing: details | Show results with:details
  37. [37]
    Miles Inc. gets German name of parent- company Bayer
    Apr 4, 1995 · Miles Inc. changed its name to Bayer Corp. yesterday, curing a decades-long headache for the famous aspirin inventor. The story behind the name ...
  38. [38]
    In Brief: Bayer AG
    Jan 16, 1995 · Bayer AG: German parent changes name of its U.S. subsidiary, Miles Inc., to Bayer Corp., effective April 1. To accompany the name change, ...<|control11|><|separator|>
  39. [39]
    Loss of Miles/Bayer left a hole in Elkhart's heart many years ago
    Feb 24, 2019 · Miles Laboratories was founded by Dr. Franklin Miles in 1884 and was privately owned until Bayer bought it in the late 1970s. Still, the ...
  40. [40]
    Bought for $1, 1MSF Former Bayer Complex Will House Nonprofit's ...
    Oct 27, 2003 · The building opened in 1938 as part of the portfolio of Miles Laboratories, which Bayer AG acquired in 1978. At its peak, the plant employed ...
  41. [41]
    Bayer Puts 1-Million-Sq.-Ft. Northern Indiana Plant on Market
    Sep 30, 2002 · That experience, they explained, stretches back 116 years, to Bayer acquisition of Miles Laboratories. "As a long-time member of the Elkhart ...<|control11|><|separator|>
  42. [42]
    Bayer plant closing in Elkhart - Indiana Economic Digest
    Nov 17, 2005 · Since Miles Inc. changed its name to Bayer Corp. in 1995, a steady stream of divisions and employees has trickled out of Elkhart. For 26 years, ...Missing: post- restructuring
  43. [43]
    Bayer announces plans to close last Michiana facility
    Feb 19, 2019 · Bayer announced Tuesday its plans to close its final facility in Michiana, located on Edison Lakes Parkway. The company will close the site after an 18-month ...
  44. [44]
    Bayer announces plans to close its last Michiana location, leaving ...
    Feb 19, 2019 · Bayer purchased Elkhart-based Miles Laboratories back in 1979. The company has slowly moved operations out of the area. The Mishawaka office was ...Missing: post- acquisition restructuring
  45. [45]
    Alka-Seltzer - Ad Age
    Sep 14, 2003 · In 1938, Alka-Seltzer's claims to remedy "systemic acidity" drew the attention of the Federal Trade Commission, which described Miles' ...
  46. [46]
    Alka‐Seltzer's $143‐Million Headache - The New York Times
    Nov 4, 1973 · The Tinker agency, then Doyle Dane Bernbach, and now Wells, Rich, Greene, created commercials for Miles that are credited with elevating the ...<|separator|>
  47. [47]
    You Probably Don't Need that Green AG1 Smoothie - McGill University
    Mar 22, 2024 · That thinking goes all the way back to Miles Laboratories. They were the first to market a one-a-day multivitamin in the 1940s, introducing ...
  48. [48]
    Should One-A-Day Be Once-A-Day? | Allen Matkins - JDSupra
    Sep 10, 2018 · Miles Laboratories pioneered the concept of daily dosing of multivitamins and minerals in the 1940s with the introduction of its One A Day brand ...
  49. [49]
    [PDF] THE ECONOMIC IMPACT OF THE PHYSICIAN SECTOR Elkhart ...
    ... economic player like Miles Laboratories when it left the area in 1992. In such a case, one would question what the loss would be to the local economy if all ...
  50. [50]
    Former Bayer building in Elkhart demolished - ABC57
    Jun 21, 2012 · The old Bayer building off of Randolph street is being demolished. The building used to be the home of the Miles Bayer Laboratory where the ...